← Back to All US Stocks

NHC Stock Analysis 2026 - NATIONAL HEALTHCARE CORP AI Rating

NHC NYSE Services-Skilled Nursing Care Facilities DE CIK: 0001047335
Recently Updated • Analysis: Apr 13, 2026 • SEC Data: 2025-12-31
BUY
72% Conf
Pending
Analysis scheduled

📊 NHC Key Takeaways

Revenue: $1.5B
Net Margin: 7.9%
Free Cash Flow: $148.6M
Current Ratio: 1.82x
Debt/Equity: 0.04x
EPS: $7.67
AI Rating: BUY with 72% confidence

Is NHC a Good Investment? Thesis Analysis

Claude

National Healthcare Corp demonstrates exceptional financial strength with fortress-like balance sheet (0.04x debt-to-equity), robust free cash flow generation ($148.6M annually), and strong liquidity. However, net income declined 2.1% despite 3.3% revenue growth, signaling margin compression in a challenged reimbursement environment.

Why Buy NHC? Key Strengths

Claude
  • + Exceptional balance sheet strength with minimal leverage (D/E 0.04x) and 31.0x interest coverage
  • + Strong free cash flow generation of $148.6M (9.8% FCF margin) with low capex intensity
  • + Solid liquidity position (1.82x current ratio) with $92.8M cash versus $40.0M long-term debt

NHC Investment Risks to Consider

Claude
  • ! Net income declining (-2.1% YoY) despite revenue growth indicates margin compression and operational pressure
  • ! Skilled nursing facility sector faces structural headwinds from Medicare/Medicaid reimbursement constraints and regulatory costs
  • ! Modest organic revenue growth of 3.3% suggests limited expansion opportunity in mature healthcare services market

Key Metrics to Watch

Claude
  • * Operating margin trend - critical indicator of pricing power and cost control in reimbursement-constrained environment
  • * Free cash flow sustainability and capital allocation (organic investment, debt reduction, shareholder returns)
  • * Medicare and Medicaid reimbursement rate changes and regulatory compliance costs impact

NHC Financial Metrics

Revenue
$1.5B
Net Income
$120.0M
EPS (Diluted)
$7.67
Free Cash Flow
$148.6M
Total Assets
$1.5B
Cash Position
$92.8M

💡 AI Analyst Insight

NATIONAL HEALTHCARE CORP presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

NHC Profitability Ratios

Gross Margin N/A
Operating Margin 8.5%
Net Margin 7.9%
ROE 11.2%
ROA 7.9%
FCF Margin 9.8%

NHC vs Default Sector

How NATIONAL HEALTHCARE CORP compares to Default sector averages

Net Margin
NHC 7.9%
vs
Sector Avg 12.0%
NHC Sector
ROE
NHC 11.2%
vs
Sector Avg 15.0%
NHC Sector
Current Ratio
NHC 1.8x
vs
Sector Avg 1.8x
NHC Sector
Debt/Equity
NHC 0.0x
vs
Sector Avg 0.7x
NHC Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is NHC Overvalued or Undervalued?

Based on fundamental analysis, NATIONAL HEALTHCARE CORP has mixed fundamental signals relative to the Default sector in 2026.

Return on Equity
11.2%
Sector avg: 15%
Net Profit Margin
7.9%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.04x
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

NHC Balance Sheet & Liquidity

Current Ratio
1.82x
Quick Ratio
1.79x
Debt/Equity
0.04x
Debt/Assets
29.6%
Interest Coverage
31.04x
Long-term Debt
$40.0M

NHC 5-Year Financial Trend & Growth Analysis

NHC 5-year financial data: Year 2021: Revenue $965.5M, Net Income $68.2M, EPS $4.44. Year 2022: Revenue $1.0B, Net Income $41.9M, EPS $2.72. Year 2023: Revenue $1.1B, Net Income $138.6M, EPS $8.99. Year 2024: Revenue $1.3B, Net Income $22.4M, EPS $1.45. Year 2025: Revenue $1.5B, Net Income $66.8M, EPS $4.34.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: NATIONAL HEALTHCARE CORP's revenue has grown significantly by 52% over the 5-year period, indicating strong business expansion. The most recent EPS of $4.34 reflects profitable operations.

NHC Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
9.8%
Free cash flow / Revenue

NHC Quarterly Performance

Quarterly financial performance data for NATIONAL HEALTHCARE CORP including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $328.7M $39.2M $2.50
Q2 2025 $279.9M $23.7M $1.52
Q1 2025 $285.8M $26.2M $1.69
Q3 2024 $277.0M $10.4M $0.68
Q2 2024 $269.6M $16.3M $1.06
Q1 2024 $258.0M $11.7M $0.76
Q3 2023 $260.2M -$2.4M $-0.16
Q2 2023 $260.1M $3.2M $0.21

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

NHC Capital Allocation

Operating Cash Flow
$185.1M
Cash generated from operations
Stock Buybacks
$14.7M
Shares repurchased (TTM)
Capital Expenditures
$36.4M
Investment in assets
Dividends Paid
$38.7M
Returned to shareholders

NHC SEC 10-K & 10-Q Filing Analysis

Access official SEC EDGAR filings for NATIONAL HEALTHCARE CORP (CIK: 0001047335)

📋 Recent SEC Filings

Date Form Document Action
Apr 2, 2026 DEF 14A ny20062027x1_def14a.htm View →
Mar 18, 2026 4 xslF345X06/rdgdoc.xml View →
Mar 16, 2026 4 xslF345X05/rdgdoc.xml View →
Mar 16, 2026 4 xslF345X05/rdgdoc.xml View →
Mar 10, 2026 4 xslF345X05/rdgdoc.xml View →

Frequently Asked Questions about NHC

What is the AI rating for NHC?

NATIONAL HEALTHCARE CORP (NHC) has an AI rating of BUY with 72% confidence, based on fundamental analysis of SEC EDGAR filings.

What are NHC's key strengths?

Claude: Exceptional balance sheet strength with minimal leverage (D/E 0.04x) and 31.0x interest coverage. Strong free cash flow generation of $148.6M (9.8% FCF margin) with low capex intensity.

What are the risks of investing in NHC?

Claude: Net income declining (-2.1% YoY) despite revenue growth indicates margin compression and operational pressure. Skilled nursing facility sector faces structural headwinds from Medicare/Medicaid reimbursement constraints and regulatory costs.

What is NHC's revenue and growth?

NATIONAL HEALTHCARE CORP reported revenue of $1.5B.

Does NHC pay dividends?

NATIONAL HEALTHCARE CORP pays dividends, with $38.7M distributed to shareholders in the trailing twelve months.

Where can I find NHC SEC filings?

Official SEC filings for NATIONAL HEALTHCARE CORP (CIK: 0001047335) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is NHC's EPS?

NATIONAL HEALTHCARE CORP has a diluted EPS of $7.67.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is NHC a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, NATIONAL HEALTHCARE CORP has a BUY rating with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.

Is NHC stock overvalued or undervalued?

Valuation metrics for NHC: ROE of 11.2% (sector avg: 15%), net margin of 7.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy NHC stock in 2026?

Our dual AI analysis gives NATIONAL HEALTHCARE CORP a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is NHC's free cash flow?

NATIONAL HEALTHCARE CORP's operating cash flow is $185.1M, with capital expenditures of $36.4M. FCF margin is 9.8%.

How does NHC compare to other Default stocks?

Vs Default sector averages: Net margin 7.9% (avg: 12%), ROE 11.2% (avg: 15%), current ratio 1.82 (avg: 1.8).

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 13, 2026 | Data as of: 2025-12-31 | Powered by Claude AI